Novo Nordisk A/S
NVO
$49.16
-$1.10-2.19%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.74B | 11.69B | 11.02B | 12.25B | 10.51B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.74B | 11.69B | 11.02B | 12.25B | 10.51B |
| Cost of Revenue | 2.80B | 1.95B | 1.82B | 1.72B | 1.67B |
| Gross Profit | 8.94B | 9.74B | 9.20B | 10.52B | 8.84B |
| SG&A Expenses | 2.71B | 2.87B | 2.27B | 2.90B | 2.44B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 3.50M | -1.97M | -105.76M | 14.88M |
| Total Operating Expenses | 7.32B | 6.60B | 5.54B | 6.16B | 5.52B |
| Operating Income | 4.43B | 5.09B | 5.47B | 6.08B | 4.98B |
| Income Before Tax | 4.00B | 5.14B | 5.22B | 5.08B | 5.07B |
| Income Tax Expenses | 863.28M | 1.11B | 1.13B | 1.05B | 1.04B |
| Earnings from Continuing Operations | 3.13B | 4.03B | 4.10B | 4.03B | 4.02B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.13B | 4.03B | 4.10B | 4.03B | 4.02B |
| EBIT | 4.43B | 5.09B | 5.47B | 6.08B | 4.98B |
| EBITDA | 4.93B | 5.73B | 6.01B | 6.33B | 5.28B |
| EPS Basic | 0.71 | 0.91 | 0.92 | 0.91 | 0.90 |
| Normalized Basic EPS | 0.66 | 0.72 | 0.74 | 0.83 | 0.71 |
| EPS Diluted | 0.70 | 0.91 | 0.92 | 0.91 | 0.90 |
| Normalized Diluted EPS | 0.66 | 0.72 | 0.73 | 0.83 | 0.71 |
| Average Basic Shares Outstanding | 4.44B | 4.44B | 4.44B | 4.45B | 4.45B |
| Average Diluted Shares Outstanding | 4.45B | 4.45B | 4.45B | 4.46B | 4.46B |
| Dividend Per Share | 0.00 | 0.57 | -- | 1.13 | 0.00 |
| Payout Ratio | 83.29% | -- | 121.49% | 0.00% | 57.08% |